LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company,
announced the pricing of an underwritten public offering of 3,750,000
shares of its common stock at a public offering price of $40.00 per
share. The offering is expected to close on or about October 25, 2016,
subject to customary closing conditions. The Company has granted the
underwriters a 30-day option to purchase up to 562,500 additional shares
of its common stock at the public offering price, less underwriting
discounts and commissions. All of the shares are being sold by Puma
Biotechnology.
Citigroup and J.P. Morgan are acting as lead book-running managers,
Credit Suisse is acting as joint book-running manager and BofA Merrill
Lynch is acting as lead manager for the offering. Stifel is acting as
co-manager for the offering.
The offering is being made pursuant to an automatically effective shelf
registration statement filed with the Securities and Exchange Commission
(SEC) on January 20, 2015. A preliminary prospectus supplement
describing the terms of the offering has been filed with the SEC and is
available on the SEC’s website at www.sec.gov.
Copies of the preliminary prospectus supplement and the accompanying
prospectus, and when available, the final prospectus supplement and the
accompanying prospectus relating to the offering may also be obtained by
contacting Citigroup Global Markets Inc., c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by phone at
(800) 831-9146; J.P. Morgan Securities LLC, Attention: Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717,
or by phone at (866) 803-9204; or Credit Suisse, Attention: Prospectus
Department, One Madison Avenue, New York, NY 10010, by telephone at
(800) 221-1037, or by email at newyork.prospectus@credit-suisse.com.
This news release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction.
Contact: